Replay available

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) Q1 2026 earnings conference call, held 2026-05-13. Replay captured from the company's public earnings webcast.

Wed, May 13, 2026 at 8:30 AMendedReplay
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Joseph Oliveto

President and Chief Executive Officer, Milestone Pharmaceuticals

Michael Wood

Host, LifeSci Advisors

Amit Hasija

Chief Financial Officer and EVP of Corporate Development, Milestone Pharmaceuticals

Brandon Fawkes

Analyst, H.C. Wainwright & Co.

Lorenz Muller

Chief Commercial Officer, Milestone Pharmaceuticals

Tiago Ford

Analyst, Raymond James

Ritu Barao

Analyst, Cowen & Company

Ted Tenthoff

Analyst, Piper Sandler

Mohit Bansal

Analyst, Wells Fargo

Replay transcript excerpt

Ladies and gentlemen, good morning and welcome to the Milestone Pharma first quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. A brief question and answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please signal the operator by pressing star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Michael Wood of LifeSci Advisors. Please go ahead. Thank you, operator. Good morning, everyone, and welcome to the Milestone Pharmaceuticals first quarter 2026 financial results and business update conference call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended March 31, 2026 and recent corporate highlights. The release can be accessed on the investors and meters section of the company's website, milestonepharma.com. Before we begin, I'd like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause actual clinical programs, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with milestones, business, and factors that could cause or contribute to such differences are described in detail in the company's filings with the SEC, including in the risk factors section of the annual report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 20, 2026. Speaking on the call today will be...

More from Milestone Pharmaceuticals Inc.